Strides Pharma Science Limited announced its financial results for the quarter and year ended March 31, 2026. The company reported a consolidated annual revenue of Rs. 48,586.83 million and a consolidated net profit of Rs. 5,745.20 million for FY2026. Reflecting strong performance, the Board has recommended a final dividend of Rs. 5 per equity share, representing a 50% payout for the financial year.
Annual Financial Performance
For the financial year ended March 31, 2026, Strides Pharma Science Limited achieved a consolidated revenue from operations of Rs. 48,586.83 million, compared to Rs. 45,653.35 million in the previous year. The consolidated net profit for the year stood at Rs. 5,745.20 million, marking a steady growth trajectory for the business. In the final quarter of the year (Q4), the company recorded a revenue of Rs. 13,234.70 million and a net profit of Rs. 1,292.81 million.
Dividend Recommendation
Recognizing the company’s financial health and commitment to shareholder value, the Board of Directors has recommended a final dividend of Rs. 5 per equity share of face value Rs. 10 each. This proposal accounts for a 50% dividend rate for the fiscal year ended March 31, 2026. The final payment is subject to approval by the shareholders at the company’s ensuing Annual General Meeting.
Strategic Outlook and Operations
The company maintains a single reportable segment, ‘Pharmaceutical’, which encompasses the development, manufacturing, and commercialization of pharmaceutical products, excluding biological drugs. The Board confirmed that the auditor’s report for both standalone and consolidated financial statements carries an unmodified opinion, underscoring the transparency and accuracy of the company’s financial disclosures.
Source: BSE
